Aurista Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 17-11-2024
- Paid Up Capital ₹ 1.50 M
as on 17-11-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 17-11-2024
- Revenue 463.36%
(FY 2023)
- Profit 104530.19%
(FY 2023)
- Ebitda 2973.12%
(FY 2023)
- Net Worth 14.74%
(FY 2023)
- Total Assets 216.12%
(FY 2023)
About Aurista Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹1.00 M.
Pramod Kumar, Manju Rani, Deepak Kaushal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239UR2021PTC012510
- Company No.
012510
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aurista Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Kumar  | Director | 11-Jun-2021 | Current |
| Manju Rani | Director | 11-Jun-2021 | Current |
| Deepak Kaushal | Director | 10-Oct-2022 | Current |
| Rahul Kumar | Director | 10-Oct-2022 | Current |
| Umesh Sharma | Director | 10-Oct-2022 | Current |
Financial Performance of Aurista Pharma.
Aurista Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 463.36% increase. The company also saw a substantial improvement in profitability, with a 104530.19% increase in profit. The company's net worth Soared by an impressive increase of 14.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurista Pharma?
Unlock access to Aurista Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aurista Parenterals Private LimitedActive 1 year 11 monthsPramod Kumar and Manju Rani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Mar 2023 | ₹1.00 M | Open |
How Many Employees Work at Aurista Pharma?
Aurista Pharma has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurista Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurista Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
